Published in Wiley Interdiscip Rev Nanomed Nanobiotechnol on February 12, 2015
Silica-coated Gd(DOTA)-loaded protein nanoparticles enable magnetic resonance imaging of macrophages. J Mater Chem B Mater Biol Med (2015) 0.80
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy. Theranostics (2016) 0.78
Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics. Biomaterials (2016) 0.75
Optical and Magnetic Resonance Imaging Using Fluorous Colloidal Nanoparticles. Biomacromolecules (2016) 0.75
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant (2006) 7.13
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
RECONSTITUTION OF ACTIVE TOBACCO MOSAIC VIRUS FROM ITS INACTIVE PROTEIN AND NUCLEIC ACID COMPONENTS. Proc Natl Acad Sci U S A (1955) 5.25
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev (2006) 4.27
Chemical exchange saturation transfer (CEST): what is in a name and what isn't? Magn Reson Med (2011) 4.08
Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev (2002) 3.35
Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) (2011) 3.33
Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release (2009) 3.08
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imaging (2009) 2.48
Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science (2013) 2.42
Biodistribution of 1.4- and 18-nm gold particles in rats. Small (2008) 2.32
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev (2010) 1.82
Biological applications of magnetic nanoparticles. Chem Soc Rev (2012) 1.76
Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc Chem Res (2013) 1.68
Core-controlled polymorphism in virus-like particles. Proc Natl Acad Sci U S A (2007) 1.66
High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. J Am Chem Soc (2008) 1.66
Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. Chem Commun (Camb) (2007) 1.63
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol (2008) 1.60
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release (2007) 1.53
Self-assembling light-harvesting systems from synthetically modified tobacco mosaic virus coat proteins. J Am Chem Soc (2007) 1.52
Understanding the toxicity of carbon nanotubes. Acc Chem Res (2012) 1.51
Magnetic resonance contrast agents from viral capsid shells: a comparison of exterior and interior cargo strategies. Nano Lett (2007) 1.51
Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med (2005) 1.48
The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech (2008) 1.46
Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm (2009) 1.45
Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules (2003) 1.42
Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm Res (2007) 1.38
Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release (2010) 1.35
Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization. J Am Chem Soc (2011) 1.30
Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.29
Viral capsids as MRI contrast agents. Magn Reson Med (2007) 1.28
Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomedicine (2007) 1.27
M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer. Nat Nanotechnol (2012) 1.27
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res (2011) 1.23
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
PEGylation as a tool for the biomedical engineering of surface modified microparticles. J Pharm Sci (2008) 1.23
Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev (2011) 1.20
Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexes. J Am Chem Soc (2011) 1.20
Virus-based nanocarriers for drug delivery. Adv Drug Deliv Rev (2012) 1.19
Predicted inactivation of viruses of relevance to biodefense by solar radiation. J Virol (2005) 1.17
The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid Nanofluidics (2012) 1.13
Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm (2012) 1.13
Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents. J Mater Chem B Mater Biol Med (2013) 1.10
A xenon-based molecular sensor assembled on an MS2 viral capsid scaffold. J Am Chem Soc (2010) 1.10
Redirecting the coat protein of a spherical virus to assemble into tubular nanostructures. J Am Chem Soc (2006) 1.09
Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology (2013) 1.05
Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett (2014) 1.04
Humans have antibodies against a plant virus: evidence from tobacco mosaic virus. PLoS One (2013) 1.00
Genome-free viral capsids as carriers for positron emission tomography radiolabels. Mol Imaging Biol (2008) 1.00
In vitro-reassembled plant virus-like particles for loading of polyacids. J Gen Virol (2006) 0.97
Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology (2013) 0.97
Transfection of neuroprogenitor cells with iron nanoparticles for magnetic resonance imaging tracking: cell viability, differentiation, and intracellular localization. Mol Imaging Biol (2006) 0.95
Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine. J Biol Phys (2013) 0.94
Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice. Nanomedicine (Lond) (2013) 0.92
Metal binding to cowpea chlorotic mottle virus using terbium(III) fluorescence. J Biol Inorg Chem (2003) 0.92
P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol Pharm (2012) 0.91
Immune responses of BALB/c mice to subcutaneously injected multi-walled carbon nanotubes. Nanotoxicology (2010) 0.90
Guiding plant virus particles to integrin-displaying cells. Nanoscale (2012) 0.90
HyperCEST detection of a 129Xe-based contrast agent composed of cryptophane-A molecular cages on a bacteriophage scaffold. Magn Reson Med (2012) 0.90
Thermal transition of native tobacco mosaic virus and RNA-free viral proteins into spherical nanoparticles. J Gen Virol (2010) 0.89
N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano (2012) 0.88
Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One (2009) 0.87
Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev (2012) 0.87
Magnetic virus-like nanoparticles in N. benthamiana plants: a new paradigm for environmental and agronomic biotechnological research. ACS Nano (2011) 0.87
Trackable and Targeted Phage as Positron Emission Tomography (PET) Agent for Cancer Imaging. Theranostics (2011) 0.87
Generation and structural analysis of reactive empty particles derived from an icosahedral virus. Chem Biol (2006) 0.85
PET Imaging and biodistribution of chemically modified bacteriophage MS2. Mol Pharm (2012) 0.85
Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des (2013) 0.82
Molecular imaging of cancer cells using a bacteriophage-based 129Xe NMR biosensor. Angew Chem Int Ed Engl (2013) 0.82
Rotavirus capsid surface protein VP4-coated Fe(3)O(4) nanoparticles as a theranostic platform for cellular imaging and drug delivery. Biomaterials (2012) 0.82
Engineered viral nanoparticles for flow cytometry and fluorescence microscopy applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.81
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology (2012) 0.81
Magnetically targeted viral envelopes: a PET investigation of initial biodistribution. IEEE Trans Nanobioscience (2008) 0.81
Synthetic virology: engineering viruses for gene delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.81
Shape matters: the diffusion rates of TMV rods and CPMV icosahedrons in a spheroid model of extracellular matrix are distinct. Biomater Sci (2013) 0.81
Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. J Virol Methods (2007) 0.81
Tobacco mosaic virus in the lungs of mice following intra-tracheal inoculation. PLoS One (2013) 0.80
Controlled ligand display on a symmetrical protein-cage architecture through mixed assembly. Small (2006) 0.79
Plant virus incorporated hydrogels as scaffolds for tissue engineering possess low immunogenicity in vivo. J Biomed Mater Res A (2014) 0.78
The aspect ratio of nanoparticle assemblies and the spatial arrangement of ligands can be optimized to enhance the targeting of cancer cells. Adv Healthc Mater (2014) 0.78
Viral protein-coating of magnetic nanoparticles using simian virus 40 VP1. J Biotechnol (2013) 0.78
Combination of pet imaging with viral vectors for identification of cancer metastases. Adv Drug Deliv Rev (2011) 0.77
Viral assembly using heterologous expression systems and cell extracts. Adv Protein Chem (2003) 0.77
Protein-based functional nanomaterial design for bioengineering applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.76
Ultrasound imaging: better contrast with vesicles. Nat Nanotechnol (2014) 0.75